Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis : scoping report

MLA

Pöhlmann, Johannes, et al. Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis : Scoping Report. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1242405117&authtype=sso&custid=ns315887.

APA

Pöhlmann, J., Mattli, R., Syleouni, M.-E., Carlander, M. J., Meier, F., Egli, P., Gerber-Grote, A., & Wieser, S. (2021). Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis : scoping report.

Chicago

Pöhlmann, Johannes, Renato Mattli, Maria-Eleni Syleouni, Maria Johanna Carlander, Flurina Meier, Philipp Egli, Andreas Gerber-Grote, and Simon Wieser. 2021. “Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis : Scoping Report.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1242405117&authtype=sso&custid=ns315887.